Coelingh K V, Winter C C
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.
J Virol. 1990 Mar;64(3):1329-34. doi: 10.1128/JVI.64.3.1329-1334.1990.
Many human parainfluenza type 3 virus (PIV3) strains isolated from children with respiratory illness are resistant to neutralization by monoclonal antibodies (MAbs) which recognize epitopes in antigenic site A or B of the fusion (F) protein of the prototype 1957 PIV3 strain. The F protein genes of seven PIV3 clinical isolates were sequenced to determine whether their neutralization-resistant phenotypes were associated with specific differences in amino acids which are recognized by neutralizing MAbs. Several clinical strains which were resistant to neutralization by site A or B MAbs had amino acid differences at residues 398 or 73, respectively. These specific changes undoubtedly account for the neutralization-resistant phenotype of these isolates, since identical substitutions at residues 398 or 73 in MAb-selected escape mutants confer resistance to neutralization by site A or B MAbs. The existence of identical changes in naturally occurring and MAb-selected neutralization-resistant PIV3 strains raises the possibility that antigenically different strains may arise by immune selection during replication in partially immune children. Three of the seven clinical strains examined had differences in their F protein cleavage site sequence. Whereas the prototype PIV3 strain has the cleavage site sequence Arg-Thr-Lys-Arg, one clinical isolate had the sequence Arg-Thr-Arg-Arg and two isolates had the sequence Arg-Thr-Glu-Arg. The different cleavage site sequences of these viruses did not affect their level of replication in either continuous simian or bovine kidney cell monolayers (in the presence or absence of exogenous trypsin or plasmin) or in the upper or lower respiratory tract of rhesus monkeys. We conclude that two nonconsecutive basic residues within the F protein cleavage site are sufficient for efficient replication of human PIV3 in primates.
从患有呼吸道疾病的儿童中分离出的许多人副流感3型病毒(PIV3)毒株,对识别1957年原型PIV3毒株融合(F)蛋白抗原位点A或B中表位的单克隆抗体(MAb)的中和作用具有抗性。对7株PIV3临床分离株的F蛋白基因进行测序,以确定其抗中和表型是否与中和MAb识别的氨基酸特异性差异相关。几株对位点A或B MAb的中和作用具有抗性的临床毒株,分别在398位或73位残基处存在氨基酸差异。这些特定变化无疑解释了这些分离株的抗中和表型,因为在MAb选择的逃逸突变体中398位或73位残基处的相同取代赋予了对位点A或B MAb中和作用的抗性。天然存在的和MAb选择的抗中和PIV3毒株中存在相同变化,这增加了在部分免疫儿童体内复制过程中通过免疫选择产生抗原性不同毒株的可能性。所检测的7株临床毒株中有3株在其F蛋白裂解位点序列上存在差异。原型PIV3毒株的裂解位点序列为Arg-Thr-Lys-Arg,一株临床分离株的序列为Arg-Thr-Arg-Arg,两株分离株的序列为Arg-Thr-Glu-Arg。这些病毒不同的裂解位点序列在连续的猴肾或牛肾细胞单层(存在或不存在外源性胰蛋白酶或纤溶酶)或恒河猴的上呼吸道或下呼吸道中均不影响其复制水平。我们得出结论,F蛋白裂解位点内两个不连续的碱性残基足以使人PIV3在灵长类动物中高效复制。